AI summary by TwinMind
How one scientist averted a national health crisis - Andrea Tone
TED-Ed
5m 32s
Frances Kelsey's Background and Education
- Fall 1960: Joined FDA as newest recruit
- Graduated high school at age 15
- McGill University Montreal: undergraduate and master's degrees in pharmacology
- University of Chicago pharmacology department: applied for research post
- Acceptance letter addressed to "Mr. Oldham" (gender confusion)
- Joked career might have ended if named Elizabeth or Mary Jane
- Earned doctorate in pharmacology at Chicago
- Stayed as faculty, conducted pioneering research on drugs and fetal safety
- 1950: Earned MD (fourth and final degree)
- By FDA joining: one of most educated, experienced scientists around
Thalidomide Assignment and Initial Review
- Assigned "easy review" as newest team member
- Application from US drug company Merrell to sell thalidomide
- Thalidomide: sedative developed in Germany
- Already widely used in dozens of countries
- Treated insomnia and workplace stress
- Anti-nausea properties made it popular for pregnant women with morning sickness
- Kelsey found Merrell's data on absorption and toxicity inadequate
- 1960: Many experts believed placental barrier shielded fetus from harm
- Kelsey's earlier animal research demonstrated opposite: drugs could pass mother to fetus through placenta
- Merrell had not tested drug on pregnant animals (standard practice at time)
- Kelsey said evidence seemed "more like testimonials than results of well-designed studies"
FDA Review Process and Merrell's Response
- Kelsey rejected Merrell's application, requested second application with better evidence
- FDA colleagues supported decision
- Merrell expected quick approval for holiday season launch (sedative sales soar)
- Instead of providing requested data, Merrell tried convincing Kelsey through calls and visits
- Merrell executives complained Kelsey was "stubborn and nit-picking"
- FDA backed Kelsey, forcing Merrell to file multiple applications
Thalidomide Adverse Effects Discovery
- Early 1961: Doctors reported nerve damage cases
- Fall 1961: Uncovered severe birth defects in pregnant women users
- Thousands of babies died in utero
- Tens of thousands born with:
- Extra appendages
- Shorter limbs
- No limbs at all
- November 1961: Thalidomide pulled from German market
- Merrell continued US approval attempts for several months before withdrawing sixth and final application
Impact and Recognition
- Kelsey kept thalidomide off multi-billion-dollar American drug market
- Became media sensation as public awareness grew
- Headlines heralded her heroism in newspapers and magazines
- President John F. Kennedy presented her award on White House lawn
- Post-thalidomide: Congress passed laws expanding FDA authority and toughening new drug application requirements
- Kelsey appointed to head agency's drug investigation branch
- Worked at FDA in different capacities into her 90s
- Legacy: privileging facts over opinions, patience over shortcuts, making evidence-based medicine foundation of continuing reforms
